Core Viewpoint - The national drug procurement initiative aims to reduce medication costs for the public while ensuring the quality and safety of generic drugs through a structured selection process [1][4]. Group 1: Procurement Details - The 11th batch of drug procurement will include 55 drugs, focusing on areas such as anti-tumor, diabetes, and cardiovascular medications [2][3]. - The selection process adheres to the principle of "no new drugs in procurement, only non-new drugs," to protect industry innovation [2][4]. - The procurement list was finalized after three screening phases, with stricter quality requirements imposed on participating companies [4][5]. Group 2: Quality and Safety Concerns - The procurement process emphasizes the need for companies to have at least two years of production experience and compliance with quality management standards [4][5]. - Concerns regarding the clinical efficacy and safety of selected generic drugs have been raised, particularly in relation to price reductions [4][6]. Group 3: Reporting and Selection Process - The procurement rules have been optimized to allow medical institutions to report quantities based on specific brands, enhancing their autonomy in drug selection [7][8]. - The agreed procurement volume will account for 60%-80% of the reported quantities, with adjustments for special categories like antibiotics [8].